Day: February 7, 2020

Apranga APB (hereinafter – the Company) hereby informs that the Supervision Service of the Bank of Lithuania (hereinafter – the SSBL) has completed an investigation on the compliance of the Company’s accounting and financial statements for 2018 with international accounting standards; and on the compliance of the Annual Report and Social Responsibility Report with the legislation (hereinafter – the investigation).By the Decision of the Director of the Supervision Service of the Bank of Lithuania issued on 3 February 2020 No. 241-20 it was decided not to apply any enforcement measures to the Company.However, the SSBL’s investigation has revealed some infringements which were recommended to be publicly disclosed:1. Annual financial statements of the Company for the year 2018 do not comply with the requirements...

APB „Apranga“ (toliau – Bendrovė) informuoja, kad Lietuvos banko Priežiūros tarnyba (toliau – LBPT) užbaigė tyrimą dėl Bendrovės buhalterinės apskaitos ir 2018 m. finansinių ataskaitų atitikties tarptautiniams apskaitos standartams bei metinio pranešimo ir socialinės atsakomybės ataskaitos atitikties teisės aktams (toliau – tyrimas).2020 m. vasario 3 d. Lietuvos banko Priežiūros tarnybos direktoriaus sprendimu Nr. 241-20 nuspręsta netaikyti APB „Apranga“ poveikio priemonių.Tačiau LBPT tyrimo metu nustatė pažeidimus, kuriuos rekomendavo atskleisti viešai:1. Bendrovė 2018 m. ataskaitose nesilaikė 16 TAS „Nekilnojamasis turtas, įranga ir įrengimai“...

REHOVOT, Israel, Feb. 07, 2020 (GLOBE NEWSWIRE) — Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today released a letter to shareholders:Dear Shareholders,Thank you for continuing to support the Company as we embark on this effort to transform into a US-focused blood diagnostics company preparing to embark on a clinical utility study with a view towards obtaining our own CPT code to allow for value-based, consistent reimbursement of an actionable blood test for breast cancer. I was asked by the Company’s Board of Directors to step in as CEO in early January, in large part, due to the prospective acquisition of Provista Diagnostics, which is a US-based blood testing company that has...

HOUSTON, Feb. 07, 2020 (GLOBE NEWSWIRE) — Sysco Corporation (NYSE: SYY), the leading global foodservice distribution company, announced today it has designed a Sustainability Bond Framework (the Framework) under which it may issue Green, Social and/or Sustainability Bonds to advance the company’s 2025 corporate social responsibility (CSR) goals.Sysco’s CSR strategy focuses on three key areas: people, products and planet, setting a clear path for the future and demonstrating the company’s continued commitment to caring for people, sourcing products responsibly and protecting the planet. The company’s 2025 CSR goals, announced in 2018, include a comprehensive set of objectives, including sourcing 20% of its electricity from renewable sources, powering 20% of its truck fleet with alternative fuels, expanding...

HOUSTON, Feb. 07, 2020 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $9.6 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius.The offering is comprised of 7,101,307 Class A Units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock at an exercise price of $1.15 per share, and 1,246,519 Class B Units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of Series A convertible preferred stock and a five-year warrant to purchase...

JERICHO, N.Y., Feb. 07, 2020 (GLOBE NEWSWIRE) — Nathan’s Famous, Inc. (NASDAQ:NATH) today reported results for the third quarter of its 2020 fiscal year that ended December 29, 2019.For the fiscal quarter ended December 29, 2019:Revenues were $21,376,000, as compared to $20,222,000 during the thirteen weeks ended December 23, 2018;Income from operations was $3,863,000, as compared to $4,896,000 during the thirteen weeks ended December 23, 2018;Adjusted EBITDA1, a non-GAAP financial measure, was $4,546,000, as compared to $5,485,000 for the thirteen weeks ended December 23, 2018;Income before provision for income taxes was $1,573,000, as compared to $13,349,000 for the thirteen weeks ended December 23, 2018;Income before provision for income taxes included a gain from the sale of real estate of $10,821,000 during the thirteen...

NEW YORK, Feb. 07, 2020 (GLOBE NEWSWIRE) — EXL (NASDAQ: EXLS), a leading Operations Management and Analytics company, today announced it has achieved placement as a Leader and Star Performer in the “Everest Group Life and Pensions (L&P) Insurance BPO Services PEAK Matrix® Assessment 2019.” The report cited EXL as a provider demonstrating double-digit growth in gaining market share and the scale of its resources employed across the L&P insurance value chain.“EXL continues to display strong growth momentum in the L&P insurance BPO/TPA market and is now more aggressively pushing its digital agenda,” said Skand Bhargava, Practice Director, Everest Group. “The company also continues to focus on delivery quality through domain-specific training and value-add services.”“We are excited...

LungFit™ PH U.S. market launch for the treatment of persistent pulmonary hypertension of the newborn (PPHN) expected calendar 4Q 2020Third pilot study for LungFit™ BRO program nearing completion of enrollment;  Results expected calendar 2Q 2020Pivotal LungFit BRO™ study on track for calendar 4Q 2020 start and calendar 2Q 2021 completionLungFit™ NTM At-Home nontuberculous mycobacteria (NTM) lung infection pilot study start targeted for mid-2020; Patients to self-administer Nitric Oxide (NO) over a 12-week periodAnimal toxicity data from multiple studies support strong safety profile of high concentration NOSave the date for Analyst Day: March 5, 2020 at 2:00 pm Eastern Time in New York CityConference Call scheduled for today, Friday, February 7th at 11:00 am ETGARDEN CITY, N.Y. and REHOVOT, Israel, Feb....

CARLSBAD, Calif., Feb. 07, 2020 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSX VENTURE:ASG) is pleased to announce that it has closed the final tranche of its non-brokered private placement offering (the “Offering”). Under the final tranche of the Offering, the Company issued 3,432,000 units (the “Units”) at a price of CDN$0.25 per Unit for aggregate gross proceeds of approximately CDN$858,000. The aggregate proceeds under the Offering were CDN$2,233,000.The Company intends to use the proceeds from the Offering for general corporate purposes. Each Unit is comprised of one common share of the Company and one half one common share purchase warrant of the Company. Each whole warrant is exercisable at a price of CDN$0.45 per common share for a period...